New Directions in Pharmacotherapy for Opioid Use Disorders
This presentation will include recently completed as well as planned studies from the NIDA-funded Clinical Trials Network (CTN), a network in which South Carolina treatment centers play a prominent role. Studies comparing long-acting, injectable formulations of buprenorphine to sublingual (SL) buprenorphine as well as studies comparing SL buprenorphine to injectable naltrexone will be described. Studies of the utilization of MAT in criminal justice and emergency room settings will be reviewed. Finally, planned studies to investigate ancillary pharmacotherapies, studies of retention strategies and investigations to try to determine optimal duration of treatment will be discussed.